-+ 0.00%
-+ 0.00%
-+ 0.00%

Mendus teams with SAHMRI to prepare Phase 2a VITAL-TFR2 trial of vididencel in CML

PUBT·07/16/2026 06:04:11
Listen to the news
Mendus teams with SAHMRI to prepare Phase 2a VITAL-TFR2 trial of vididencel in CML
  • Mendus signed an agreement with SAHMRI to support preparations for the Phase 2a VITAL-TFR2 trial of vididencel in CML.
  • VITAL-TFR2 targets patients who relapsed after a prior treatment-free remission attempt; it will test whether vididencel can improve durable remission off TKIs.
  • Trial planning advances alongside VITAL-CML; initial safety and tolerability data from VITAL-CML are expected in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mendus AB (publ) published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.